Source comparison
GHRH analogs versus ghrelin-receptor secretagogues
The mechanistic split within this group deserves emphasis because it is frequently blurred in popular sources. GHRH analogs (tesamorelin, sermorelin, CJC-1295) and ghrelin-receptor agonists (ipamorelin, and the GHRP family more broadly) stimulate GH through tw
This comparison does not assign a generated winner or score.
- The mechanistic split within this group deserves emphasis because it is frequently blurred in popular sources. GHRH analogs (tesamorelin, sermorelin, CJC-1295) and ghrelin-receptor agonists (ipamorelin, and the GHRP family more broadly) stimulate GH through two distinct receptors that can act complementarily. GHRH analogs act on the GHRH receptor to raise the amplitude of GH pulses; ghrelin-receptor secretagogues act on GHS-R1a to both stimulate GH release and blunt somatostatin’s inhibitory tone. This is the rationale behind popular “GHRH + secretagogue” pairings in the research space: activating both pathways can produce a larger GH response than either alone. It is important to stress, however, that combination approaches are studied far less rigorously than tesamorelin monotherapy, that they are not FDA-approved, and that stacking amplifies not only the GH signal but also the theoretical IGF-1-related and glucose-related concerns discussed above — without the monitoring framework t